Evidence map›Paper›PMID 26675138›Full record

ArticleThe EMBO journal2016

Convergence of cMyc and β-catenin on Tcf7l1 enables endoderm specification.

Gillian Morrison, Roberta Scognamiglio, Andreas Trumpp, Austin Smith

Open access · hybridAbstract read
In one paragraph

Article in The EMBO journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. BioMed research international · 2021
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Wnt Transcriptional Switch: TLE Removal or Inactivation?BioEssays : news and reviews in molecular, cellular and developmental biology · 2018
    Review
  17. Article
  18. Article
  19. Review
  20. Gene expression and pathway analysis ofWorld journal of stem cells · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Gillian MorrisonWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK gillian.morrison@ed.ac.uk austin.smith@cscr.cam.ac.uk.
Roberta ScognamiglioDivision of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Andreas TrumppDivision of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Austin SmithWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK Department of Biochemistry, University of Cambridge, Cambridge, UK gillian.morrison@ed.ac.uk austin.smith@cscr.cam.ac.uk.
German Cancer Research Center · DEHeidelberg Institute for Stem Cell Technology and Experimental Medicine · DEMedical Research Council · GBUniversity of Cambridge · GB

Funding

Medical Research Council G1001028Medical Research Council G1100526Medical Research Council MC_PC_12009Wellcome Trust 97922
6 · The paper itself

Abstract

The molecular machinery that directs formation of definitive endoderm from pluripotent stem cells is not well understood. Wnt/β-catenin and Nodal signalling have been implicated, but the requirements for lineage specification remain incompletely defined. Here, we demonstrate a potent effect of inhibiting glycogen synthase kinase 3 (GSK3) on definitive endoderm production. We find that downstream of GSK3 inhibition, elevated cMyc and β-catenin act in parallel to reduce transcription and DNA binding, respectively, of the transcriptional repressor Tcf7l1. Tcf7l1 represses FoxA2, a pioneer factor for endoderm specification. Deletion of Tcf7l1 is sufficient to allow upregulation of FoxA2 in the presence of Activin. In wild-type cells, cMyc contributes by reducing Tcf7l1 mRNA, while β-catenin acts on Tcf7l1 protein. GSK3 inhibition is further required for consolidation of endodermal fate via upregulation of Sox17, highlighting sequential roles for Wnt signalling. The identification of a cMyc/β-catenin-Tcf7l1-FoxA2 axis reveals a de-repression mechanism underlying endoderm induction that may be recapitulated in other developmental and patho-logical contexts.

Indexed as

Cell DifferentiationSignal TransductionActivinsAnimalsbeta CateninCells, CulturedEmbryonic Stem CellsEndodermGene Expression RegulationGlycogen Synthase Kinase 3Hepatocyte Nuclear Factor 3-betaMiceProto-Oncogene Proteins c-mycTranscription Factor 7-Like 1 ProteinActivinsbeta CateninFoxa2 protein, mouseGlycogen Synthase Kinase 3Hepatocyte Nuclear Factor 3-betaMyc protein, mouseProto-Oncogene Proteins c-mycTcf7l1 protein, mouseTranscription Factor 7-Like 1 Proteinembryonic stem cellsendodermFoxA2MycTcf7l1

Identifiers

PMID26675138
PMCPMC4741304
OpenAlexW2188164280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.